Harry Erba, MD
Medical Oncology · Ann Arbor, MINPI 1508942566
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $676,007 of the $1,109,088 with a category attached, or 61.0%. 25 manufacturers reported payments, led by Incyte Corporation at 35.7% of the total. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $1312.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$396K
- Servier Pharmaceuticals LLC$110K
- Daiichi Sankyo Inc.$110K
- Bristol Myers Squibb$92K
- AbbVie$89K
- Novartis$80K
- plus $232K from 19 others
Across 262 payments — averaging $12,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$779K
- Sumitomo Pharma America, Inc.$588K
- AbbVie$386K
- Novartis$285K
- Servier Pharmaceuticals LLC$253K
- Daiichi Sankyo Inc.$235K
- plus $692K from 17 others
What the payments were for
- Consulting fees$304,38127%
- Speaking & faculty fees$676,00761%
- Travel & lodging$112,86610%
- Food & beverage$15,8231%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 303 | $395,779 |
| Servier Pharmaceuticals LLC | 92 | $110,300 |
| Daiichi Sankyo Inc. | 92 | $109,876 |
| Bristol Myers Squibb | 55 | $91,947 |
| AbbVie | 58 | $88,552 |
| Novartis | 50 | $80,216 |
| Jazz Pharmaceuticals Inc. | 73 | $73,624 |
| Agios Pharmaceuticals, Inc. | 61 | $59,406 |
| Syndax Pharmaceuticals, Inc. | 15 | $20,769 |
| Pfizer | 8 | $16,303 |
| Astellas Pharma US Inc | 5 | $15,374 |
| Genentech USA, Inc. | 3 | $9,942 |
| Taiho Oncology, Inc. | 3 | $6,472 |
| Sumitomo Pharma America, Inc. | 2 | $6,020 |
| Amgen | 5 | $5,293 |
| Rigel Pharmaceuticals, Inc. | 4 | $3,938 |
| Gilead(2 entities) | 4 | $3,375 |
| Daiichi Sankyo Europe GmbH | 1 | $3,257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,640 |
| Genentech, Inc. | 2 | $2,346 |
| Janssen Global Services, LLC | 3 | $2,112 |
| AstraZeneca | 1 | $1,028 |
| E.r. Squibb & Sons, L.L.C. | 1 | $346 |
| Seagen Inc. | 1 | $120 |
| Stemline Therapeutics Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,109,088 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 54 | $941,181 |
| TibsovoIvosidenib | 32 | $923,620 |
| OjjaaraMomelotinib Dihydrochloride | 21 | $577,577 |
| VenclextaVenetoclax | 101 | $449,072 |
| SprycelDasatinib | 24 | $413,713 |
| ScemblixAsciminib Hydrochloride | 16 | $370,819 |
| IdhifaEnasidenib Mesylate | 12 | $350,986 |
| BosulifBosutinib | 23 | $347,778 |
| XospataGilteritinib Fumarate | 15 | $310,832 |
| IclusigPonatinib Hcl | 12 | $176,388 |
| Imatinib Mesylate | 30 | $115,806 |
| PegasysPeginterferon Alfa-2a | 14 | $60,634 |
| EliquisApixaban | 11 | $6,257 |
| Acyclovir | 130 | $1,311 |
| Mercaptopurine | 18 | $832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $395,779 | $941,18154 claims |
| Servier Pharmaceuticals LLCTibsovo | $110,300 | $923,62032 claims |
| AbbVieVenclexta | $88,552 | $449,072101 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $346 | $413,71324 claims |
| NovartisScemblix | $80,216 | $370,81916 claims |
| PfizerBosulif, Eliquis | $16,303 | $354,03534 claims |
| Bristol Myers SquibbIdhifa | $91,947 | $350,98612 claims |
| Astellas Pharma US IncXospata | $15,374 | $310,83215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $2,640 | $176,38812 claims |
| Genentech, Inc.Pegasys | $2,346 | $60,63414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Ann Arbor
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
- Rashmi ChughAnn Arbor$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.